Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

A third oral antiplatelet inhibitor has been approved by the FDA to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). Ticagrelor is an adenosine diphosphate receptor P2Y12 inhibitor similar to clopidogrel and prasugrel. It is marketed by AstraZeneca as Brilinta.

Ticagrelor Tablets (Brilinta™)